WCO-IOF 2016: Greater BMD increase after 1 year of romosozumab vesus teripratide
How to Cite
OrthoEvidence. WCO-IOF 2016: Greater BMD increase after 1 year of romosozumab vesus teripratide. ACE Report. 2016;5(5):15. Available from: https://myorthoevidence.com/AceReport/Report/8930
Superior gains in bone mineral density and estimated strength at the hip for romosozumab compared with teriparatide in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
436 postmenopausal women with osteoporosis who had been administered oral bisphosphonate therapy for 3 years prior were randomized in a phase 3 clinical trial to subcutaneous romosozumab or subcutaneous teriparatide. The purpose of this study was to compare the change in bone mineral density after 1 year of treatment between the two groups. Reported results demonstrated a significantly greater inc...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE